Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.

Dangouloff-Ros V, Cervera P, Carbonell N, Arrivé L.

Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):213-5. doi: 10.1016/j.clinre.2013.01.007.

PMID:
23498774
2.

Lenalidomide in multiple myeloma.

Richardson PG, Mitsiades C, Hideshima T, Anderson KC.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73. Review.

PMID:
16925483
3.

Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.

Mariz JM, Esteves GV.

Curr Opin Oncol. 2012 Jan;24 Suppl 2:S3-11. doi: 10.1097/01.cco.0000410243.84074.dc. Review.

PMID:
22245806
4.

[Lenalidomide in hematological malignancies---review].

Jin X, Zhang YZ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Feb;20(1):205-9. Review. Chinese.

PMID:
22391198
5.

Lenalidomide in myelodysplastic syndrome and multiple myeloma.

Shah SR, Tran TM.

Drugs. 2007;67(13):1869-81. Review.

PMID:
17722955
6.

Thalidomide and lenalidomide in the treatment of multiple myeloma.

Kumar S, Rajkumar SV.

Eur J Cancer. 2006 Jul;42(11):1612-22. Review.

PMID:
16750621
7.

Pomalidomide for patients with multiple myeloma.

Gras J.

Drugs Today (Barc). 2013 Sep;49(9):555-62. doi: 10.1358/dot.2013.49.9.2017031. Review.

PMID:
24086951
8.

Lenalidomide and its role in the management of multiple myeloma.

Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A.

Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865. Review.

PMID:
18533796
9.

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.

Palumbo A, Dimopoulos M, San Miguel J, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P.

Blood Rev. 2009 Mar;23(2):87-93. doi: 10.1016/j.blre.2008.07.003. Review.

PMID:
18774632
10.

Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.

Lacy MQ, Tefferi A.

Leuk Lymphoma. 2011 Apr;52(4):560-6. doi: 10.3109/10428194.2011.552139. Review.

PMID:
21338284
11.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
12.

Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.

Briani C, Torre CD, Campagnolo M, Lucchetta M, Berno T, Candiotto L, Padua L, Ermani M, Cavaletti G, Zambello R.

J Peripher Nerv Syst. 2013 Mar;18(1):19-24. doi: 10.1111/jns5.12002.

PMID:
23521639
13.

Current therapeutic uses of lenalidomide in multiple myeloma.

Hideshima T, Richardson PG, Anderson KC.

Expert Opin Investig Drugs. 2006 Feb;15(2):171-9. Review.

PMID:
16433596
14.

Lenalidomide as a novel treatment of acute myeloid leukemia.

Chen Y, Borthakur G.

Expert Opin Investig Drugs. 2013 Mar;22(3):389-97. doi: 10.1517/13543784.2013.758712. Review.

PMID:
23316859
15.

Thalidomide and lenalidomide in multiple myeloma.

Mazumder A, Jagannath S.

Best Pract Res Clin Haematol. 2006;19(4):769-80. Review.

PMID:
16997182
16.

Advances in oral therapy in the treatment of multiple myeloma.

Doss DS.

Clin J Oncol Nurs. 2006 Aug;10(4):514-20. Review.

PMID:
16927905
17.

Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.

Dreicer R.

Curr Oncol Rep. 2007 Mar;9(2):120-3. Review.

PMID:
17288877
18.

Clinical experience with thalidomide and lenalidomide in multiple myeloma.

Moehler T.

Curr Cancer Drug Targets. 2012 May;12(4):372-90. Review.

PMID:
22229246
19.

[The use of lenalidomide in the treatment of multiple myeloma].

Holánek M, Hájek R.

Klin Onkol. 2010;23(2):67-72. Review. Czech.

PMID:
20465083
20.

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.

Raje N, Hideshima T, Anderson KC.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1239-47. Review.

PMID:
17020458

Supplemental Content

Support Center